Last Updated: 19 Sep 2024
Executive Summary
23AndMe Holding Co (ME) is a consumer genetics and research company with a market capitalization of approximately $169.7 million. The company's latest stock price is $0.34. ME reported a loss per share of $1.31 for the quarter ending June 30, 2024, with a quarterly revenue growth of -0.336% year-over-year. The company has a negative EBITDA of $235.1 million and a trailing Price-to-Sales ratio of 0.852.
Company Overview
23AndMe is headquartered in Sunnyvale, California, and has an additional office in Mountain View, California. The company is dedicated to developing a genetic database to unlock knowledge that leads to rapid discovery of new drug development targets. 23AndMe's mission is to empower individuals with their genetic information to improve their health and well-being.
Fundamental Analysis
ME's financial performance has been mixed in recent quarters. The company reported a loss per share of $1.31 for the quarter ending June 30, 2024, on revenue of $199.2 million. This represents a decrease in revenue of 0.336% year-over-year. The company's gross profit margin was 66.8%, and its operating margin was -1.78%. 23AndMe has a negative EBITDA of $235.1 million and a trailing Price-to-Sales ratio of 0.852.
Technical Analysis
ME's stock price has been trading in a range between $0.29 and $1.09 over the past 52 weeks. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is at 34.5, indicating that the stock is oversold.
Short Term Outlook
ME's stock price is likely to remain under pressure in the short term. The company's financial performance has been mixed, and the stock is trading below its moving averages. The RSI is also indicating that the stock is oversold.
Long Term Outlook
ME's long-term outlook is more positive. The company is a leader in the field of consumer genetics, and it has a strong research and development pipeline. The company's mission to empower individuals with their genetic information is a noble one, and it is likely to resonate with consumers in the long term.
Analyst Recommendations
The majority of analysts covering ME have a "Hold" rating on the stock. The average analyst target price is $1.21.
